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THE PlA2 POLYMORPHISM OF GPIIb-IIIa
Ischemic heart disease (IHD) and adverse events after
coronary stent placement represent polygenic disorders.
They correspond to complex traits induced not only by
multiple genes but also by the interaction of these genes
with the environment. Multiple loci likely to be implicated
in IHD are polymorphic, such that there are two or more
variant forms of the gene in the population. These variants
have been created by mutations that can change the coding
sequence of the gene in question. A missense mutation, for
example, would produce a different form of the encoded
protein, whose function might be slightly altered compared
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with the ancestor protein. Alternatively, the mutation,
might fall within the regulatory domains of a gene, thereby
changing the level of expression of the gene product and/or
when and where the gene is being activated. The specific
impact of such mutations is further dependent on a variety
of factors, both genetic and environmental.
The platelet antigen 2 (PlA2) polymorphism represents
one such variant that has been implicated in arterial throm-
bosis (1–3). Due to the substitution of a cytosine for a
thymidine at position 1565 in exon 2 of the glycoprotein
IIIa (GPIIIa or integrin Beta3) gene, the Pl
A2 variant
displays a proline instead of a leucine at amino acid 33 (4).
Hence, the ancestor gene is called PlA1 and the variant gene
PlA2, such that individuals can be PlA1/A1 homozygous,
PlA1/A2 heterozygous or PlA2/A2 homozygous. Glycoprotein
IIIa, together with GPIIb, constitutes the fibrinogen recep-
tor (GPIIb-IIIa), whose engagement represents the final
common pathway for platelet activation (5). Therefore,
GPIIIa with its PlA2 polymorphism is positioned as a
candidate gene that contributes to arterial thromboembolic
complications. The PlA2 polymorphism affects the structure
of GPIIb-IIIa, an assumption that was supported by the
discovery of the PlA2 variant as the cause for a severe form
of neonatal alloimmune thrombocytopenia.
We initially observed a high prevalence of PlA2 positivity
in a population of siblings of patients with a history of
premature IHD (IHD manifestations before age 60) (6) and
in patients with severe unstable coronary syndromes (7). In
complex traits, it is unlikely that individual genes have an
effect that would account for more than a few percent of the
variance. Consistent with this concept, in a meta-analysis,
we have found that the relative risk of myocardial infarction
(MI) associated with PlA2 is small (1.2) but significant (p 5
0.034) (8). Several studies have not confirmed the associa-
tion between PlA2 and MI, in particular, the Physicians’
Health Study (9). Hence, as a consequence of such discrep-
ancy among well conducted epidemiological studies, the
link between PlA2 and spontaneous MI is perceived as
controversial (2). In contrast with epidemiological data,
most studies on the molecular effect of the PlA2 polymor-
phism on GPIIb-IIIa function have been consistent. These
studies have shown that the L33P mutation results in
increased platelet responsiveness (10,11).
Genetic factors can influence illnesses in very specific
ways. Considering that a clinical diagnosis of MI encom-
passes a complex phenotype, the relative impact of the PlA2
polymorphism on MI may vary according to multiple
factors, including the presence or absence of ST elevation,
associated diseases like diabetes, gender, age, environment
and medications. Studies of patients who have died sud-
denly and at a young age can be highly instructive, as the
culprit lesion can be identified and characterized, and the
number of contributing modifiers is often limited. Indeed,
sudden death is a prominent first manifestation of coronary
artery disease in younger individuals, such that sudden death
victims do not have the opportunity to benefit from drugs
that could interfere with the effect of a gene variant.
Mikkelsson et al. (12) have reported that the prevalence of
PlA2 is elevated in sudden death victims whose coronary
vessels contain a thrombus. They also reported that PlA1/A1
homozygous individuals have a heightened atherosclerotic
plaque burden compared with their PlA2 counterparts.
These results suggest that PlA2, in conjunction with other
genetic and environmental risk factors, might contribute to
driving the course of atherosclerosis toward a path of
coronary plaque rupture and thrombus formation.
ENDOVASCULAR CORONARY PROCEDURES AND PlA2
Catheter-based intervention with stent placement has be-
come a preferred management for patients with symptom-
atic coronary disease (both acute coronary ischemic syn-
dromes and acute MI). Although associated with a risk that
is not negligible, the procedure has become safer because of
technological advances and the availability of powerful
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antithrombotic drugs (13). The use of intracoronary stents
has improved the immediate and short-term efficacy of
endovascular procedures by maximizing acute procedural
luminal gain and reducing the unfavorable geometric vas-
cular remodeling of stenotic coronary vessels. We have
hypothesized that, to be efficient, an antithrombotic strategy
must target the impact of specific susceptibility genes
implicated in coronary thrombosis under various clinical
circumstances (14). This principle is pertinent to strategies
directed towards minimizing thromboembolic complica-
tions after stent revascularization. Platelet antigen 2 was the
first platelet polymorphism implicated in thromboembolic
complications associated with stent placement (15).
Several classes of drugs are clinically utilized to reduce
platelet activity during coronary stenting: 1) acetylsalicylate
(ASA), 2) thrombin antagonists (unfractionated heparin,
mainly), 3) thienopyridine derivatives (clopidogrel and ticlo-
pidine), and 4) GPIIb-IIIa antagonists (ReoPro or abcix-
imab, Tirofiban or aggrastat, and Integrilin or eptafibitide).
The role of dipyridamole for stent patients has not yet been
established but could be of interest for drug combination
strategies. Two combinations of drugs have been highly
successful in reducing adverse events associated with coro-
nary stent placement: a) ASA plus an antithrombin plus a
thienopyridine derivative or b) aspirin plus an antithrombin
plus a GPII-IIIa blocker. It is likely that the multidrug
approach has the potential of covering a larger number of
“thrombotic susceptibility genes” compared with single
agent therapy. Experiments performed in vitro have consis-
tently shown an increased responsiveness to agonists of
platelets displaying the PlA2 polymorphism (10,11). In this
context, the study of Kastrati et al. (17) published in this
issue can be viewed as investigating whether standard
antithrombotic strategies have reached a sufficient level of
control for the thrombotic diathesis conferred by the PlA2
polymorphism.
PlA2 AND ADVERSE
EVENTS AFTER STENT PLACEMENT
There have been three studies published on the topic of PlA2
and adverse events after stent revascularization. Walter et al.
(15) studied 318 consecutive patients who received a coro-
nary stent for indications of dissection, acute occlusion or
suboptimal angioplasty. The primary end points of death,
MI, stent thrombosis and coronary bypass surgery were
followed over a period of 30 days after stent placement. All
patients received aspirin and heparin during the procedure.
Ticlopidine, 250 mg per day, was started and given for the
next four weeks, in combination with aspirin (100 mg per
day), which was continued indefinitely. Occlusion of the
stent vessel was more frequent in PlA2 positive individuals
(9.5% in PlA2 positive patients vs. 1.9% in PlA1/A1 homozy-
gous, odds ratio: 5.26, p 5 0.01). There was also an excess
of MI in the PlA2 positive patient group.
Laule et al. (16) studied 1,000 consecutive patients with
angiographically confirmed coronary artery disease, 653 of
whom received intervention (280 with stent placements and
102 with directional coronary atherectomy). A composite
end point of death, MI and target vessel revascularization
(TVR) was followed for 30 days after intervention. All
patients received aspirin and heparin during the procedure
and after the procedure aspirin (100 mg indefinitely).
Stented patients also received ticlopidine 500 mg daily for
four weeks. A total of 41 patients reached the 30-day
composite end point (6.3%). For the 653 who received
intervention, the odds ratio for the composite end point
(PlA2 positive vs. PlA1/A1) was 1.36, 1.46 for TVR and 1.31
for MI (nonsignificant). For the stented patients, the odds
ratio for the composite end point (PlA2 positive vs. PlA1/A1)
was 1.42, 1.78 for TVR and 1.24 for MI (nonsignificant).
Due to the small number of homozygous PlA2/A2, the
analysis pooled PlA2/A2 with PlA1/A2 patients.
The study by Kastrati et al. (17) included 1,759 consec-
utive patients with stable or unstable angina and successful
stent placement. The composite end point of death, MI and
urgent revascularization was followed for 30 days after stent
placement. All patients received aspirin (100 mg twice a
day) indefinitely and ticlopidine (250 mg twice a day) for
four weeks. Patients with residual thrombi or flow limiting
dissection received abciximab (bolus plus 12 h infusion).
Angiographic stent thrombosis occurred in 2.1% of PlA2
positive, versus 1.7% of the PlA1/A1 homozygous patients
(nonsignificant). Death and Q-wave MI were significantly
more frequent in PlA2 carriers. Moreover, PlA2/A2 homozy-
gous patients (n 5 46) had either a clear trend or a
significantly higher event rate compared with heterozygous
and PlA1/A1 homozygous patients. The primary end point
was reached in 5.4% for PlA1/A1 patients, PlA1/A2 4.8% and
PlA2/A2 13.0% (p 5 0.06); the incidence of death or MI was
4.3% for PlA1/A1 patients, PlA1/A2 4.2% and PlA2/A2 13.0%
(p 5 0.02), and the incidence of angiographic stent throm-
bosis was 1.7% for PlA1/A1 patients, PlA1/A2 1.5% and
PlA2/A2 8.7% (p 5 0.002). PlA2 positive patients with stent
thrombosis tended to be younger than PlA1/A1 homozygous
patients with stent thrombosis. In a multivariate model, the
PlA2/A2 genotype was associated with an adverse outcome
after stenting (odds ratio: 2.6), compared with the PlA1/A1
genotype. Only 12.1% of the patients received abciximab.
From the analysis of these three studies that surveyed
2,357 patients for a period of 30 days, one may conclude
that the PlA2 polymorphism of GPIIIa represents a risk
factor for adverse events in patients undergoing coronary
stenting. Although all three studies were conducted by
expert investigators, they differ in their complication rates
and in their conclusion relative to the strength of the impact
of PlA2 on adverse events. Although some unrecognized
factor(s) may have contributed to such a discrepancy, it is
notable that the studies were not uniform in terms of the
antithrombotic regimen provided to the patients (Table 1).
For example, in the study by Walter et al. (15), whose
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findings support that PlA2 has a powerful effect on adverse
events (OR:5.3), the patients received only 100 mg of ASA
and 250 mg of ticlopidine daily for four weeks. In the report
of Laule et al. (16), patients received 100 mg of ASA and
500 mg of ticlopidine (but no GPIIb-IIIa blocker), and the
effects of PlA2 was less pronounced (OR:1.5). Finally,
Kastrati and colleagues in this issue (17) have reported an
even smaller effect of PlA2 (OR:1.2), and their patients
received 200 mg of ASA, 500 mg of ticlopidine, and a small
minority of patients received abciximab.
It is tempting to speculate that differences in the PlA2
effect among studies was due to the strength of the anti-
thrombotic regimen. As indicated earlier, we have hypoth-
esized that, to be efficient, an antithrombotic strategy must
target a specific susceptibility gene implicated in coronary
thrombosis, including thrombotic events that follow stent
placement. According to this theory, most PlA1/A1 patients
may find enough protection against adverse events after
stent placement from an antithrombotic strategy that in-
cludes heparin, ASA ($325 mg daily) and a thienopyridine
derivative (full dose) for four to six weeks. The PlA1/A2
heterozygous patients would need the same triple therapy,
but a dose of ASA of 160 mg daily might suffice (14), while
the duration of the administration of thienopyridine deriv-
ative (clopidogrel, 75 mg daily) might need to be extended
for a period of six to 12 months. Whereas the “toughest nuts
to crack”, the PlA2/A2 homozygous platelets, may need a
GPIIb-IIIa blocker to lower their risk to the level of PlA1/A1
or PlA1/A2 patients, in addition to receiving ASA ($325 mg
daily), clopidogrel (75 mg daily for 6 to 12 months) and
heparin. Additional large scale studies will be needed to test
the usefulness of stratifying procedural risk with knowledge
of PlA status in patients undergoing catheter based inter-
ventions. Considering important issues of safety and in-
creasing cost, it might be of interest not only to stratify risk
with genomic information but then target the use of
increasingly powerful and costly antithrombotic strategies to
those patients who will derive the greatest benefits.
PlA2 AND RESTENOSIS
In a previous study of 1,150 consecutive patients with
successful coronary stent placements and followed for an
average of 163 days, Kastrati et al. (18) showed that PlA2
positive patients have a significantly higher rate of restenosis
(defined angiographically as $50% diameter stenosis at six
months after procedure): 53.1% in PlA2/A2, 46.1% in
PlA1/A2 and 38.4% in PlA1/A1 patients. The effect of PlA2 on
restenosis rate was particularly pronounced for women: 52%
restenosis for PlA2 positive versus 33% for PlA1/A1 homozy-
gous women compared with 45% restenosis for PlA2 positive
versus 40% for PlA1/A1 homozygous men.
The use of stents for coronary interventions has expanded
our understanding of the pathophysiology of restenosis, as it
has nearly eliminated the component of “recoil” of the vessel
wall from the restenotic process. In the presence of a stent,
the contribution of neointimal hyperplasia (smooth muscle
cell proliferation) to restenosis is more important than after
conventional balloon angioplasty. Platelet adhesion and
aggregation does contribute substantially to restenosis by
promoting the migration and growth of smooth muscle cells
(19). Even when acute stent thrombosis is efficiently pre-
vented in PlA2 carriers using combination antiplatelet ther-
apy with ASA, heparin and ticlopidine, the residual platelet
accumulation might be sufficient to promote restenosis. It
may, therefore, be reasonable to extend the duration of the
administration of a thienopyridine such as clopidogrel,
which causes fewer chronic hematological side effects than
ticlopidine, to a full six-month course for patients with the
PlA2 polymorphism. Such genomic-based therapeutic deci-
sions are currently being tested and could have a substantial
effect on the efficacy and the cost of antiplatelet therapy in
the context of stent placement and restenosis.
Other polymorphisms have been studied in the context of
restenosis. The blood level of angiotensin-converting en-
zyme (ACE) has been linked to an insertion/deletion (I/D)
polymorphism of the ACE gene, such that DD genotype
carriers have a higher level of ACE than either ID or II.
Although, the I/D polymorphism is not associated with
restenosis after balloon angioplasty, the D allele is a risk
factor for restenosis after coronary stent implantation (20).
In contrast, the HPA-3 polymorphism of platelet GPIIb
(Bak) is not associated with an increase in the risk of
thrombosis and restenosis over one year after coronary stent
placement (21).
In summary, over the past few years, we have seen an
exponential rise of genetic information that may turn out to
be of great relevance not only for assessment of risk for
individual patients but also for the design of tailored
Table 1. PlA2 and Stent Thrombosis
n ASA ACT > 250 Ticlid GPIIb-IIIa-B OR
Walter (15) 318 100 1 250 2 5.3*
Laule (16) 280 100 1 500 2 1.5 (NS)
Kastrati (17) 1,759 200 1 500 12% 1.2†
In the report of Laule et al. (16), stent thrombosis rate was calculated from target vessel revascularization and myocardial
infarction rates. Odds ratio (OR) are used to estimate risk associated with PlA2.
*p , 0.05 for PlA2 positive patients (at least one PlA2 allele: PlA1/A2 1 PlA2/A2); †p . 0.05 for PlA2 positive patients, whereas
OR for stent thrombosis in PlA2/A2 homozygous patients was 5.1 (p , 0.05). ASA or acetylsalicylic acid was provided at the
indicated daily dose in mg. Ticlid 250 or 500 indicates the daily dose in mg. of ticlopidine used for each study. ACT . 250
indicates that patients were receiving a dose of heparin sufficient to maintain an activated clotting time (ACT) beyond 250 s. The
GPIIb-IIIa-B column refers to patients receiving a GPIIb-IIIa blocker (abciximab).
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therapeutic strategies, the pharmacogenetic approach to
therapy. By utilizing a pharmacogenetic approach to therapy
in patients undergoing percutaneous coronary intervention
with stent placement, we should be able to tailor the
combination of antiplatelet drugs that most accurately
suppress risk for acute thrombosis and prevent restenosis,
thereby enhancing the clinical benefit, without exposing the
patient to the unnecessary risk of bleeding and society, in
general, to excess health care costs.
Reprint requests and correspondence: Dr. Pascal J. Goldschmidt-
Clermont, Heart and Lung Institute, 514 Medical Research
Facility, 420 W. 12th Street, Columbus, Ohio 43210. E-mail:
goldschmidt-1@medctr.osu.edu.
REFERENCES
1. Nurden AT. Platelet glycoprotein IIIa polymorphism and coronary
thrombosis. Lancet 1997;350:1189–91.
2. Goldschmidt-Clermont PJ, Roos CM, Cooke GE. Platelet PlA2
polymorphism and thromboembolic events: from inherited risk to
pharmacogenetics. J Thromb 1999;8:89–103.
3. Bray PF. Integrin polymorphisms as risk factors for thrombosis.
Thromb Haemost 1999;92:337–44.
4. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens,
PlA1 and PlA2, are associated with a leucine33/proline33 amino acid
polymorphism in membrane glycoprotein IIIa and are distinguishable
by DNA typing. J Clin Invest 1989;83:1778–81.
5. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrom-
botic strategy. Circulation 1995;92:2373–80.
6. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, et al. Higher
prevalence of GPIIIa PlA2 polymorphism in siblings of patients with
premature coronary heart disease. Arch Pathol Lab Med 1999;123:
1223–9.
7. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet
glycoprotein receptor as an inherited risk factor for coronary throm-
bosis. N Engl J Med 1996;334:1090–4.
8. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-
analysis of studies on the association of the platelet PlA polymorphism
of glycoprotein IIIa and risk of coronary heart disease. Unpublished
data.
9. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner
K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of
myocardial infarction, stroke and venous thrombosis. Lancet 1997;
349:385–8.
10. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet
aggregability associated with platelet GPIIIa PlA2 polymorphism: the
Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;
19:1142–7.
11. Michelson AD, Furman MI, Goldschmidt-Clermont PJ, et al. Platelet
GPIIIa PlA polymorphisms display different sensitivities to agonists.
Circulation 2000;101:1013–8.
12. Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein IIIa/Pl(A)
polymorphism associates with progression of coronary artery disease
and with myocardial infarction in an autopsy series of middle-aged
men who died suddenly. Arteroscler Thromb Vasc Biol 1999;19:2573–8.
13. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet
1999;353:227–31.
14. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-
Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet
1998;351:1253.
15. Walter DH, Schachinger V, Elsner M, Dimmeler S, Zeiher AM.
Platelet glycoprotein IIIa polymorphisms and risk of coronary stent
thrombosis. Lancet 1997;350:1217–9.
16. Laule M, Cascorbi I, Stangl V, et al. A1/A2 polymorphism of
glycoprotein IIIa and association with excess procedural risk for
coronary catheter interventions: a case-controlled study. Lancet 1999;
353:708–12.
17. Kastrati A, Koch W, Gawaz M, et al. PlA polymorphism of glyco-
protein IIIa and risk of adverse events after coronary stent placement.
J Am Coll Cardiol 2000;36:84–9.
18. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of
platelet glycoprotein IIIa and risk of restenosis after coronary stent
placement. Circulation 1999;99:1005–10.
19. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R.
Inhibition of neointimal smooth muscle accumulation after angio-
plasty by an antibody to PDGF. Science 1991;253:1129–32.
20. Amant C, Bauters C, Bodart JC, et al. D allele of the angiotensin
I-converting enzyme is a major risk factor for restenosis after coronary
stenting. Circulation 1997;96:56–60.
21. Bottiger C, Kastrati A, Koch W, et al. Polymorphism of platelet
glycoprotein IIb and risk of thrombosis and restenosis after coronary
stent placement. Am J Cardiol 1999;84:987–91.
93JACC Vol. 36, No. 1, 2000 Goldschmidt-Clermont et al.
July 2000:90–3 Editorial Comment
